Abstract:Abstract Background In the last 2 decades, the introduction of biological therapies has been a significant milestone in the management of inflammatory bowel diseases. Despite the recent emergence of new biological therapies and small molecules, Anti-TNF agents still play a crucial role in treatment and still being used as first line biologic treatments rather than anti-integrins and anti-cytokines in quite a number of countries.Although many studies have been conducted previously to compare the efficacy of these drugs, there is still not a clear conclusion. In this study, we aimed to compare the persistence of infliximab (IFX) to adalimumab (ADA) in the treatment of Crohn's at a tertiary IBD center. Methods This was a retrospective cohort analysis of patients with Crohn's disease either received adalimumab or infliximab as a first line biologic treatment. A total of 411 patients were included to this analysis. Demographic information such as gender, age, montreal classification, smoking and prior medications were noted from patients electronic medical records. Weighted Kaplan-Meier and Cox models were used to assess the outcomes. Results Out of the 411 patients included in the study, 165 had used infliximab, and 246 had used adalimumab as a first-line treatment. Age and gender of the patients in both groups did not differ from each other statistically. 87% of the patients treated with adalimumab and 84% of the patients treated with infliximab were thiopurine experienced. Montreal classification differed between two groups (in IFX group, 60% of the patients had either sticturing or penetrating behaviour where as in ADA group, only 46% of the patients had either sticturing or penetrating behaviour, p<0.05). In ADA group, only 48% of the patients were receiving concomitant azathioprine treatment where as in IFX group, 60% of the patients were receiving concomitant azathioprine treatment. Primary non-response rates were not different between IFX and ADA group, 4.5% vs 4.6% respectively. In addition, clinical response rates after first year were 73.8% and 72.8% respectively. Drug persistency rates of adalimumab and infliximab in moderate to severe ulcerative colitis patients were not statistically different from each other (Figure 1). Conclusion In conclusion, it seems that there is no difference in drug persistence rates and in efficacy rates of the medications between infiximab and adalimumab treated moderate to severe Crohn's disease patients. Although disease character and concomitant treatment presence differ between two groups, these differences did not show any significant effect.

Adalimumab bei M. Crohn nach Abszess

Morbus Crohn: bester Schutz vor penetrierenden Komplikationen durch TNF-α-Antikörper?

Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series

Upadacitinib zur Behandlung von mittelschwerem bis schwerem Morbus Crohn

The Choice Trial: Adalimumab Demonstrates Safety, Fistula Healing, Improved Quality of Life and Increased Work Productivity in Patients with Crohn'S Disease Who Failed Prior Infliximab Therapy

Abatacept bremst rheumatoide Arthritis

Efficacy and safety of adalimumab in crohn's disease: Meta-analysis of placebo-controlled trials

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring

P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine

Evaluation of the Efficacy and Safety of Adalimumab in Crohn's Disease

P920 Efficacy and Drug Adherence Rates of Anti TNF Drugs in patients with Crohn's Disease: A Single Tertiary IBD Center Cohort

[Therapy of complicated Crohn's disease]

Mirikizumab for the treatment of chronic antibiotic-refractory pouchitis

P700 The efficacy of adalimumab combined with surgery for rectovaginal fistula in Crohn's disease:a single-center retrospective study

Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)

Multiple Sclerosis - Like Demyelinating Lesions During Adalimumab Treatment in a Case with Crohn's Disease

Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae

ABDOMEN BECKEN – Colonkarzinom: CT-gestützte Beurteilung der zirkumferentiellen Resektionsränder

Colitis ulcerosa: Ustekinumab gleich effektiv bei späten und frühen Respondern

P298 Adherence to diagnostic and treatment recommendations for the management of acute severe ulcerative colitis: a prospective and multinational study

Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab